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Introduction
Atopic dermatitis (AD) is an inflammatory skin disease that 
is characterised by extreme pruritis and frantic scratching. 
This induces papulation, excoriation, bleeding, oozing and 
crusting, secondary infection, and ultimately, thickening 
or lichenification.1-4 It is a chronic disease, with remission 
periods and flare-ups.3,5 
Although dermatitis can occur on any part of the body, there 
are typically affected locations that vary with age.4-6
• In infants, extensor surfaces, cheeks and the scalp are 
mainly affected, but the nappy area is often spared. 
• In childhood, typical localisation has a flexural 
distribution, seen mainly around the front of the elbow 
area, back of the knees, insides of the wrists and 
ankles, as well as around the neck. 
• In adults, a similar pattern to that observed in childhood 
is seen, but it is increasingly localised and lichenified. 
The buttocks and hands are frequently involved.
The prevalence of AD is high, particularly in the paediatric 
population. If not treated adequately, AD has both physical 
and psychological ramifications.3,5,6 The incidence of AD in 
adults in South Africa is not recorded in the literature, but 
data are available regarding children and adolescents. The 
South African Family Practice Journal reported on a study 
conducted in Cape Town among schoolchildren, aged 13-14 
years. A one-year prevalence rate of 8.3%, which increased 
to 13.3% on follow-up, was observed in this group. In three- 
to 11-year-old Xhosa children, a one-year prevalence rate of 
1-2.5% was documented.4
While AD is a childhood disease, it can progress into 
adulthood. It is estimated that about 60% of childhood 
cases resolve by early adolescence, but dry and irritable skin 
often persists. Recurrences in adults are not uncommon.2,3 
Concomitant atopic diseases, such as asthma and allergic 
rhinitis, as well as family history of AD, are predictive of a 
more persistent course.2,5
Diagnosis
Traditionally, the Hanifin and Rajika diagnostic criteria, 
which consist of four major and 23 minor criteria, have been 
used as a basis of diagnosis.6 However, there is a lack of 
standardisation around the clinical assessment and criteria 
that are used.3 Variations of the above criteria are applied by 
different authorities.
A prerequisite to diagnosis is evidence of itchy skin or 
pruritis, as well as three or more of the following major 
criteria:3-6
• Typical morphology and distribution: visible flexural 
lichenification or linearity in adults, and
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• visibly affected facial and extensor areas in infants and 
children.
• History of generally dry skin.
• History of skin creases being affected.
• Personal or family history of atopy (asthma, allergic 
rhinitis and atopic dermatitis).
• Chronic or chronically relapsing dermatitis.
• Onset before the age of two years in patients older than 
four years.
Listed below are some minor AD features:2,4-6
• Xerosis (dry skin), dry hair and lips
• Raised serum immunoglobulin E (IgE)
• Wool intolerance
• Tendency toward cutaneous infections (especially 
Staphylococcus aureus and herpes simplex) or impaired 
cell-mediated immunity 
• Palmar hyperlinearity  
• Lateral thinning of the eyebrows
• Infant cradle cap  
• Facial pallor
• Recurrent conjunctivitis
• Food allergies or intolerance
• Disease flares with emotional changes
• Increased pruritis when sweating
• Double fold of lower eyelid.
A number of other dermatological manifestations present 
in a similar way to AD. Therefore, it is imperative that 
a differential diagnosis is carried out to exclude these 
dermatological conditions.5 Table I gives a list of possible 
differential diagnoses. 
Treatment
Individualised therapy is necessary because of the 
complex nature of AD as a disease which involves genetic, 
environmental and immunological factors.9 The treatment 
of AD is directed at symptomatic relief, skin hydration, and 
reduction of inflammation.10 Figure 1 depicts a summary of 
available AD treatment modalities.
Topical corticosteroids
Topical corticosteroids are the mainstay of therapy for 
acute exacerbations. Their anti-inflammatory effect on the 
skin is induced through various mechanisms.3,12 It has been 
purported that they have an antimitotic activity. This effect is 
attributed to their efficacy in treating scaling dermatoses, as 
well as their ability to cause dermal thinning due to fibroblast 
inhibition.12 The extent to which they induce cutaneous 
vasoconstriction and inhibit inflammation corresponds with 
their potency.3,12
Topical corticosteroids can be subdivided into four groups. 
The South African classification is listed below:13
• Very potent: Group IV
• Potent: Group III
• Moderately potent: Group II
• Weak: Group I.
Table II outlines the different available preparations in South 
Afica, as well as their respective potencies. 
Better absorption of topical corticosteroids is observed 
in areas of inflammation and desquamation compared to 
normal skin, and absorption occurs more readily through the 
outer dermis in infants than through the skin of adults.12 In 
addition, increased permeability to topical corticosteroids is 
noted at anatomical sites with a thin epidermis like the face, 
compared to thick-skinned areas, such as the palms and 
soles.3,12 Absorption also depends on the vehicle carrying 
the preparation, for expample ointments result in enhanced 
absorption and are semi-occlusive. Creams, on the other 
hand, are usually less potent.12
The choice of topical corticosteroid is determined by the 
nature of the condition that is being treated. Generally, best 
practice is to start with the lowest potency agent that is 
appropriate to the severity, and to use it for as short a time 
as possible. In children, short durations of therapy with low-
potency corticosteroids are recommended. The adverse 
effect profile of higher potency topical corticosteroids has 
limited their use in children, as well as for treatment of 
facial areas. Limiting high-potency corticosteroids applied 
to areas other than the face and the inner aspects of the 
thighs and axillae, as well as to once-daily applications, 
reduce the incidence of side-effects.3,12 The use of topical 
corticosteroids should be discontinued once the skin 
condition has resolved.5,12 Clinical trials have shown that, 
when used for up to four weeks, these agents are safe and 
effective in the treatment of AD.5 
Although topical corticosteroids are safer compared to 
systemic glucocorticoids, systemic side-effects can occur, 
particularly with super-potent and potent drugs, or extensive 
use of lower-potency agents.12 The adverse effects of topical 
corticosteroids are discussed in more detail in this article. 




Red, shiny, scaly lesions affecting the nappy area 
in infants. An absence of family history.
Psoriasis Lesions distributed over the extensor surfaces, 
scalp and buttocks. Pitted nails.
Irritant contact 
dermatitis
History of exposure to irritants. Rash in area of 
exposure. Damage to skin barrier. Absence of 
family history.
Insect bites Symmetric distribution around the scalp, neck, 
face and/or extremities. Erythemous crops with 




Hypersensitivity reaction following sensitisation 
to a substance. May be superimposed on atopic 
dermatitis.
Scabies Severe pruritis; J- or S-shaped burrows, 5-10 mm 
in length on palms, soles, genitalia and between 
fingers.
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Systemic agents for severe, resistant cases:
• Ciclosporin
• aAzathioprine





• bUVA for acute flares
• cUVB for chronic disease




• Psychological approaches 
Active treatment Supportive treatment
Topical corticosteroids: mainstay or first-line 
treatment of acute flare-ups
Emollient creams: to treat xerosis, and  
reduce the need for corticosteroids
Topical calcineurin inhibitors:  
second-line agents
Sedating antihistamines: dubious role in 
pruritis, but indicated for sleep disturbance 
and co-morbid allergies
aCoal tar: alternative for patients with 
mild-to- moderate AD. Has anti-inflammatory 
and anti-pruritc effects. May be useful in 
lichenified lesions.
Antibiotics: for Staphylococcus infections
Atopic dermatitis diagnosis
a = There are mixed results, or limited evidence, regarding efficacy due to the lack of proper randomised trials, b = ultraviolet type A; c = ultraviolet type B, d = psoralen-potentiated ultraviolet A
Figure 1: Available treatment modalities for atopic dermatitis2-5,7,10,11
Table II: Available topical corticosteroids in South Africa12-14





Clobetasol propionate 0.05% Cream, ointment or scalp lotion Adults Resistant, thick lesions. Palms, soles 
and scalp.
Diflucortolone  valerate 0.3% Ointment
Potent: 
Group III
Beclometasone dipropionate 0.025% Cream Adults Thick lesions. Palms, soles and scalp.
Betamethasone valerate 0.1% Cream or ointment
Betamethasone dipropionate 0.05% Cream or ointment
Diflucortolone valerate 0.1% Fatty ointment
Fluocinolone acetonide 0.025% Cream, ointment or gel
Fluticasone propionate 0.05% Cream
Fluticasone propionate 0.005% Ointment
Hydrocortisone butyrate 0.1% Cream, ointment, lotion, or topical 
emulsion
Methylprednisol-one aceponate 0.1% Cream, milk, ointment or fatty ointment




Betamethasone valerate 0.05% Cream Adults and 
children 
Body area is affected extensively, 
excluding face and thin skinned areas.
Clobetasone butyrate 0.05% Ointment
Weak: 
Group I
Hydrocortisone acetate 0.5% and 1% Cream or ointment Adults, children 
and infants
Face, folds, and genitals. Also for 
extensive use.
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Calcineurin inhibitors
Tacrolimus and pimecrolimus are classified as calcineurin 
inhibitors.5,15 This article focuses on tacrolimus, a macrolide 
lactone immunosuppressant. It exerts an inhibitory effect 
on T-lymphocyte activation, and also modulates the 
release of inflammatory mediators from skin mast cells and 
basophils.10,15,16 Primarily, it inhibits the phosphatase activity 
of calcineurin. Calcineurin is an essential component in 
the series of events that are necessary in the early stages 
of T-cell activation. In summary, tacrolimus modulates 
the key cellular mediators that are imperative in AD 
pathogenesis.9,15,16 
Pharmacokinetically, tacrolimus is a relatively large and 
highly lipophilic molecule with a strong affinity for the skin. 
It exhibits rate-limiting absorption. As the skin heals, there 
is a proportionate reduction in the absorption of tacrolimus.9 
Although tacrolimus penetrates the skin, systemic 
absorption is minimal.9,10  In clinical trials, systemic blood 
levels were found to be below the limit of quantification.1,10 
Serum concentrations were shown to be minimal in a three-
week, phase II, randomised, double-blind, multicentre 
study, which was designed to investigate absorption of 
0.03%, 0.3% and 0.1% tacrolimus preparations.1 Based on 
this, systemic side-effects are expected to be minimal, if 
not absent.9,15 More detail on adverse effects is supplied in 
this article. 
Comparative data on topical corticosteroids vs. 
tacrolimus
A number of studies have been conducted in an effort to 
establish the safety and efficacy of tacrolimus compared 
to either vehicle base or different potencies of topical 
corticosteroids. Outlined below are some of these studies, 
as well as their results. 
Kapp et al reported on two short-term, corticosteroid-
controlled trials. These were double-blind, randomised, 
multicentre, comparative studies.9 Refer to Table III for a 
summary of the study design and results in the adult arm. 
In adults, there was rapid improvement of symptoms 
across all study arms. Also noted was an improvement 
in disease status, and this was progressive in all three 
groups, as assessed by the modified Eczema Area and 
Severity Index (mEASI). There was no statistically significant 
difference in the mEASI score between tacrolimus 0.1% 
and hydrocortisone butyrate 0.1%. Improvement was also 
noted in the tacrolimus 0.03% group, although significantly 
less than in the other two groups (p-value < 0.5 for both 
comparisons).9 Table IV gives a summary of results in the 
paediatric arm. 
In children, both tacrolimus treatment groups showed 
a statistically significant improvement compared to the 
hydrocortisone acetate group (p-value ≤ 0.001 for both 
comparisons). Tacrolimus 0.1% was significantly better 
compared to the 0.03% formulation (p-value < 0.05).9
Table III: Different strengths of tacrolimus ointment vs. hydrocortisone 
butyrate9,16
Study design Duration: Three weeks
Number of participants: 570 adult patients 












bPGE 49.2% 37.6% 51.4%
cDS 85.0% 79.9% 79.2%
Skin burning 8.7% 6.8% 1.2%
a = Modified eczema area and severity index, b = physician’s global evaluation of clinical 
response: percentage of patients with 90% improvement or more, c = percentage of patients 
with ≥ 50% improvement in disease status
Table IV: Different strengths of tacrolimus ointment vs. hydrocortisone 
acetate9,16
Study design Duration: Three weeks
Number of participants: 560 children aged 2-15 years












bPGE 48.4% 38.5% 15.7%
cDS 83.5% 80.2% 51.4%
Skin burning 5.6% 1.1% 1.2%
a = Modified eczema area and severity index, b = physician’s global evaluation of clinical 
response: percentage of patients with 90% improvement or more, c = percentage of patients 
with ≥ 50% improvement in disease status
Table V: Tacrolimus 0.1% vs. hydrocortisone-based preparations9,16,17
Study design Duration: Maximum 6 months
Number of participants: 972 adults
Atopic dermatitis severity: Moderate to severe
Regimen: Twice-daily applications
Primary end point:  ≥ 60% improvement in 
amEASI at 3 months
The mean percentage reduction in mEASI and 
median reduction in bDQLI was also measured at 
3 months
Treatment Tacrolimus 0.1% Hydrocortisone 
butyrate 1%:  trunk and 
extremities 
Hydrocortisone acetate 
1%: head and neck











a = Modified eczema area and severity index; b = Dermatology quality of life index (a higher 
score represents a lower quality of life)
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The overall results of these two studies show that in the 
short term, tacrolimus is as effective as moderately potent 
to potent topical corticosteroids, and more effective 
compared to mild or weak-potency topical corticosteroids.9 
Tacrolimus was also shown to have a similar efficacy to a 
moderately potent steroid in a phase III, randomised, open-
label study, comparing tacrolimus 1% to betamethasone 
valerate 0.12% over three weeks.16
Long-term data are also available. In a six-month 
comparative trial, Reitamo et al investigated the difference 
in efficacy between tacrolimus 1% and hydrocortisone 
butyrate 1% applied to the trunk and extremities, as well 
as hydrocortisone acetate 1% applied to head and neck 
areas.17 Table V tabulates the results. 
A greater number of patients responded to tacrolimus, 
compared to the hydrocortisone arm. The difference was 
statistically significant, with a p-value of < 0.001.17 An 
improvement was also noted on the health-related quality 
of life (HRQOL) with tacrolimus, compared to the topical 
corticosteroids.16
In other long-term, non-comparative studies, in which both 
adults and children were observed for one year, prolonged 
tacrolimus use showed progressive and sustained 
improvement in AD symptoms.9
Adverse effects
Transient skin burning is the main adverse drug reaction 
observed with use of tacrolimus.2,5,9 Generally, this is mild to 
moderate in intensity, and does not necessitate withdrawal 
of treatment as it diminishes over time.9,13,16 Other side-
effects include mild, transient pruritis, and skin erythema. 
All these side-effects are limited to the application areas.9,16 
As a topical immunomodulatory agent, tacrolimus carries the 
theoretical risk of increasing skin infections, such as herpes 
simplex infections, eczema herpeticum, fungal dermatitis, 
furunculosis, or warts.10,13,15,18 Some studies reported a higher 
incidence of viral skin infections during initial treatment with 
tacrolimus, compared to corticosteroids. Other studies did 
not.9,10,16 Overall, long-term treatment (six to 12 months) 
is not associated with an increased cutaneous infection 
prevalence. Therefore, tacrolimus does not seem to impair 
cell-mediated immunity.9,10,16,18 However, it is important to 
note that application of tacrolimus preparations to infected 
areas is not recommended.9,13,18
Acne is one problem for which a causal relationship with 
long-term use of the drug cannot be ruled out.16 Flushing, 
especially with alcohol ingestion, has also been reported in 
a number of studies.11,13,16 
An increased risk of malignancies is another concern.13,15,16 
As such, there is a black box warning against tacrolimus, 
issued by the US Food and Drug Administration (FDA) 
in 2005, against the potential risk of development of 
malignancies, mainly lymphoma and skin cancer. This was 
done because of a lack of long-term safety data at the time, 
and is based on information derived from animal studies.2,5,19
However, to date, there are no data to suggest that 
tacrolimus is associated with an increased risk of cancer 
in either children or adults.9 No increased risk of non-
melanoma skin cancer was found in post hoc reviews, and 
neither was squamous cell skin cancer reported in any 
clinical trials using tacrolimus ointment.9,10,16 A literature 
search also did not produce any evidence to confirm any 
malignancy risk, but some authors are still concerned.4,10,18 
Nevertheless, tacrolimus carries a warning about minimal 
exposure to sunlight or ultraviolet light, as a precautionary 
measure against local malignancies.5,18 Alternatively, patients 
can be counselled to use sun-protection creams.5,9,10,15,18
Adverse drug reactions associated with the use of 
corticosteroids include skin atrophy, striae, telan-giectasia, 
acne, glaucoma, adrenocortical insufficiency, and in 
extreme cases, Cushing syndrome.5,12,16,17 However, there is 
no conclusive evidence that correctly used topical agents 
cause significant systemic side-effects.5,18 In fact, literature 
suggests that when used for periods of up to four weeks, 
topical corticosteroids are safe and effective in treating AD 
flare-ups.5 Conversely, it’s the long-term use or overuse that 
is associated with adverse effects.2,5
Regarding skin atrophy, no cases were reported as a result 
of using tacrolimus. On the contrary, in a 12-month study 
of tacrolimus 0.1% in adults, some patients experienced 
a reversal of symptoms. It was unclear whether this was 
due to the absence of steroids, or directly attributable to 
tacrolimus.9 
Tacrolimus’ atrophogenic potential was specifically invest-
igated in a randomised, phase II, double-blind, placebo-
controlled trial with 14 AD patients and 12 healthy subjects. 
Tacrolimus 0.1% and 0.3%, bethamethasone valerate 0.1%, 
and the vehicle were applied twice, on day one, and again 
three to four days later, to unaffected abdominal skin and 
occluded with bandages. Skin thinning was only observed 
with betamethasone.9
In contrast, four 16-week randomised trials with topical 
corticosteroids failed to show any clinically significant skin 
thinning. Patients’ and parents’ concerns about topical 
corticosteroid use may be out of proportion to the true risk.2 
In summary, many experts agree that skin thinning arising 
from use of topical corticosteroids is minimal, if they are 
used intermittently and correctly.2,4,5,18 
Interestingly, in the phase III bethamethasone 0.12% 
comparative study mentioned earlier, the overall safety 
ratings by patients were 88% for tacrolimus, and 91% for 
the cortisone preparation.16
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Discussion 
The above results suggest that tacrolimus 0.1% is as 
effective as potent topical corticosteroids, and more 
effective than mild topical corticosteroids such as 
hydrocortisone acetate 1%, for treating atopic dermatitis in 
the short term. Long-term efficacy and safety are even more 
promising. Having examined the different studies, as well as 
the adverse effect profile of both topical corticosteroids and 
tacrolimus, the therapeutic positioning of tacrolimus in AD 
has to be queried. 
In South Africa, tacrolimus (Protopic®) is registered for use 
in children from the age of two years (0.03% strength), as 
well as in adults and adolescents from the age of 16 years 
(both 0.03% and 0.1% strengths). The 0.03% strength is to 
be applied initially as a thin layer twice daily to affected skin 
until the lesion clears. If this fails or results are inadequate, 
then the 0.1% preparation should be applied. If there is 
no improvement after three weeks, treatment should be 
stopped. In patients aged two to 15, the 0.03% strength 
may be applied twice daily for up to three weeks, and 
then the application reduced to once daily until the lesion 
clears.13
Topical corticosteroids are effective in most patients.5,18 
Given the fact that tacrolimus 0.1% is about 1.4-3.6 times 
more expensive per 30 g than moderately potent and potent 
original steroid preparations,20 the cost-effectiveness of 
topical tacrolimus vs. steroids still needs to be established.4
Several authorities recommend that tacrolimus be used as 
a second-line therapy, for moderate-to-severe AD in the 
following scenarios:
• For face and neck areas, where high potency steroids 
would be required to control symptoms.9,10,18
• Where long-term treatment with steroids is required.10,18
• In patients with evident signs of steroid toxicity.18
• In patients who are resistant to topical corticosteroids 
(rarely seen.)2,9,10,18
• In patients who are intolerant to conventional 
therapies.2,9,10
The National Institute for Health and Clinical Excellence 
(NICE) gives the following recommendation: “Topical 
tacrolimus is recommended, within its licensed indications, 
as an option for the second-line treatment of moderate-
to-severe atopic eczema in adults and children aged 2 
years and older that has not been controlled by topical 
corticosteroids, where there is a serious risk of important 
adverse effects from further topical corticosteroid 
use, particularly irreversible skin atrophy”. NICE also 
recommends that topical corticosteroids are to be used 
as first-line treatment for episodic worsening (flare-ups) of 
atopic eczema. They should be used intermittently, in order 
to reduce exposure to corticosteroids.21
Conclusion
Tacrolimus offers an alternative to the treatment of 
moderate-to-severe AD and steroid-resistant AD. It may 
be useful in treating AD at sensitive sites such as the face, 
where the use of potent topical steroids carries a high risk 
of skin thinning and telangiectasia.1 Tacrolimus 0.1% may 
also be useful for patients who depend on the constant use 
of potent steroids. The cost-effectiveness, as well as long-
term risk of infections and cancers, remain to be determined 
in the South African context.4,18 
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